RxDoctor Payments DataLook up a doctor →

Roger Williams, MD

Interventional Cardiology · Tupelo, MSNPI 1568572709

Payments from drug & device makers

$11,018in general payments, 2019–2025

Across 232 payments — averaging $47.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • Abbott$671
  • Medtronic$653
  • Boston Scientific$560
  • Penumbra, Inc.$494
  • Thrombolex, Inc.$402
  • plus $4K from 44 others

What the payments were for

  • Travel & lodging$541%
  • Food & beverage$7,06499%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,018 in reported general payments places this provider in the 55th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$456,456
Medicare patients
1,877
Services billed
11,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban127$97,045
EliquisApixaban100$84,663
Repatha SureclickEvolocumab75$66,368
EntrestoSacubitril/Valsartan21$20,650
BrilintaTicagrelor25$14,454
Praluent PenAlirocumab21$12,176
Ranolazine ErRanolazine96$9,158
Metoprolol Succinate389$4,550
Clonidine42$3,209
Ezetimibe165$2,842
Carvedilol407$2,679
Diltiazem 24hr Er (Cd)Diltiazem Hcl108$2,161
Propafenone Hcl61$2,082
Diltiazem 24hr ErDiltiazem Hcl72$2,014
ClopidogrelClopidogrel Bisulfate191$1,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$234$97,045127 claims
PfizerEliquis$217$84,663100 claims
NovartisEntresto$299$20,65021 claims
AstraZenecaBrilinta$95$14,45425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →